Management of Red Cell Alloimmunization

doi:10.1017/9781108564434.011

Chapter 10 - Management of Red Cell Alloimmunization

from Red Cell Alloimmunization

Published online by Cambridge University Press: 21 October 2019

Inge L. van Kamp and

Edited by

Anthony Johnson and

Mark D. Kilby: Affiliation:
University of Birmingham
Anthony Johnson: Affiliation:
University of Texas Medical School at Houston
Dick Oepkes: Affiliation:
Leids Universitair Medisch Centrum

Book contents

Get access

Summary

Red cell alloimmunization in pregnancy, or hemolytic disease of the fetus and newborn (HDFN), has long been a major cause of perinatal morbidity and mortality. No antenatal treatment was available up to the 1960s and the only option was thus (preterm) induction, to enable neonatal treatment. This changed with the introduction of intrauterine intraperitoneal transfusion in 1963, although the complication risk of these and the later introduced ultrasound-guided intravascular transfusions long remained substantially high.

Type: Chapter
Information: Fetal Therapy
Scientific Basis and Critical Appraisal of Clinical Benefits
, pp. 91 - 98

DOI: https://doi.org/10.1017/9781108564434.011 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Bowman, JM, Pollock, JM, Penston, LE. Fetomaternal transplacental hemorrhage during pregnancy and after delivery. Vox Sang. 1986; 51: 117–21.Google Scholar

Nederlandse Vereniging voor Obstetrie & Gynaecologie (NVOG) (2009). Erytrocytenimmunisatie en zwangerschap: Versie 2.1. https://www.nvog.nl/wp-content/uploads/2018/03/Erytrocytenimmunisatie-en-zwangerschap_.pdf Google Scholar

Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 181: Prevention of Rh D Alloimmunization. Obstet Gynecol. 2017; 130: e57–70.Google Scholar

Qureshi, H, Massey, E, Kirwan, D, Davies, T, Robson, S, White, J, Jones, J, Allard, S, British Society for Haematology. BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn. Transfus Med. 2014; 24: 8–20.Google Scholar

Levine, P. Serological factors as possible causes in spontaneous abortions. J Hered. 1943; 34: 71–80.Google Scholar

Zwiers, C, Koelewijn, JM, Vermij, L, van Sambeeck, J, Oepkes, D, de Haas, M, van der Schoot, CE. ABO incompatibility and RhIG immunoprophylaxis protect against non-D alloimmunization by pregnancy. Transfusion. 2018; 58: 1611–17.CrossRef Google Scholar PubMed

Royal College of Obstetricians and Gynaecologists (2014). Green-top Guideline 65: The Management of Women with Red Cell Antibodies during Pregnancy. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg65 Google Scholar

ACOG. Practice Bulletin No. 192: Management of alloimmunization during pregnancy. Obstet Gynecol. 2018; 131: e82–90.Google Scholar

Rijksinstituut voor Volksgezondheid en Milieu (RIVM) (2018). Draaiboek prenatale screening infectieziekten en erytrocytenimmunisatie: Versie 6.0. https://www.rivm.nl/documenten/draaiboek-prenatale-screening-infectieziekten-en-erytrocytenimmunisatie Google Scholar

National Blood Authority Australia (2015). Patient Blood Management Guidelines: Module 5 Obstetrics and Maternity. https://www.blood.gov.au/pbm-module-5 Google Scholar

Centraal Begeleidingsorgaan (2011). Richtlijn Bloedtransfusie. http://nvb-trip-symposium.nl/wp-content/uploads/2017/08/Richtlijnbloedtransfusie2011.pdf Google Scholar

Koelewijn, JM, de Haas, M, Vrijkotte, TG, Bonsel, GJ, van der Schoot, CE. One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy. Transfusion. 2008; 48: 1721–9.Google Scholar

Mayne, S, Parker, JH, Harden, TA, Dodds, SD, Beale, JA. Rate of RhD sensitisation before and after implementation of a community based antenatal prophylaxis programme. BMJ. 1997; 315: 1588.Google Scholar

van der Ploeg, CPB, Schönbeck, Y, Oomen, P, Vos, K. Prenatale Screening Infectieziekten en Erytrocytenimmunisatie (PSIE) Procesmonitor 2015. Bilthoven: RIVM, TNO, 2017.Google Scholar

Hendrickson, JE, Delaney, M. Hemolytic Disease of the fetus and newborn: modern practice and future Investigations. Transfus Med Rev. 2016; 30: 159–64.Google Scholar

Scheffer, PG, van der Schoot, CE, Page-Christiaens, GC, de Haas, M. Noninvasive fetal blood group genotyping of rhesus D, c, E and of K in alloimmunised pregnant women: evaluation of a 7-year clinical experience. BJOG. 2011; 118: 1340–8.Google Scholar

Slootweg, YM, Lindenburg, IT, Koelewijn, JM, van Kamp, IL, Oepkes, D, de Haas, M. Predicting anti-Kell-mediated hemolytic disease of the fetus and newborn: diagnostic accuracy of laboratory management. Am J Obstet Gynecol. 2018; 219: 393.e1–393.e8.Google Scholar

van Dijk, BA, Dooren, MC, Overbeeke, MA. Red cell antibodies in pregnancy: there is no ‘critical titre’. Transfus Med. 1995; 5: 199–202.Google Scholar

Oepkes, D, van Kamp, IL, Simon, MJ, Mesman, J, Overbeeke, MA, Kanhai, HH. Clinical value of an antibody-dependent cell-mediated cytotoxicity assay in the management of Rh D alloimmunization. Am J Obstet Gynecol. 2001; 184: 1015–20.CrossRef Google Scholar PubMed

Zwiers, C, van Kamp, I, Oepkes, D, Lopriore, E. Intrauterine transfusion and non-invasive treatment options for hemolytic disease of the fetus and newborn – review on current management and outcome. Expert Rev Hematol. 2017; 10: 337–44.Google Scholar

Mari, G, Deter, RL, Carpenter, RL, Rahman, F, Zimmerman, R, Moise, KJ Jr., et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative group for Doppler assessment of the blood velocity in anemic fetuses. N Engl J Med. 2000; 342: 9–14.Google Scholar

Zimmerman, R, Carpenter, RJ Jr., Durig, P, Mari, G. Longitudinal measurement of peak systolic velocity in the fetal middle cerebral artery for monitoring pregnancies complicated by red cell alloimmunisation: a prospective multicentre trial with intention-to-treat. BJOG. 2002; 109: 746–52.Google Scholar

Oepkes, D, Brand, R, Vandenbussche, FP, Meerman, RH, Kanhai, HH. The use of ultrasonography and Doppler in the prediction of fetal haemolytic anaemia: a multivariate analysis. Br J Obstet Gynaecol. 1994; 101: 680–4.Google Scholar

Chitkara, U, Wilkins, I, Lynch, L, Mehalek, K, Berkowitz, RL. The role of sonography in assessing severity of fetal anemia in Rh- and Kell-isoimmunized pregnancies. Obstet Gynecol. 1988; 71: 393–8.Google Scholar

Dukler, D, Oepkes, D, Seaward, G, Windrim, R, Ryan, G. Noninvasive tests to predict fetal anemia: a study comparing Doppler and ultrasound parameters. Am J Obstet Gynecol. 2003; 188: 1310–14.CrossRef Google Scholar PubMed

Oepkes, D, Seaward, PG, Vandenbussche, FP, Windrim, R, Kingdom, J, Beyene, J, Kanhai, HH, Ohlsson, A, Ryan, G, DIAMOND Study Group. Doppler ultrasonography versus amniocentesis to predict fetal anemia. N Engl J Med. 2006; 355: 156–64.Google Scholar

Bang, J, Bock, JE, Trolle, D. Ultrasound-guided fetal intravenous transfusion for severe rhesus haemolytic disease. BMJ (Clin Res Ed). 1982; 284: 373–4.Google Scholar

Moise, KJ Jr. Management of rhesus alloimmunization in pregnancy. Obstet Gynecol. 2008; 112: 164–76.Google Scholar

Nicolaides, KH, Soothill, PW, Clewell, WH, Rodeck, CH, Mibashan, RS, Campbell, S. Fetal haemoglobin measurement in the assessment of red cell isoimmunisation. Lancet. 1988; 1: 1073–5.Google Scholar

Society for Maternal-Fetal Medicine, Mari, G, Norton, ME, Stone, J, Berghella, V, Sciscione, AC, Tate, D, Schenone, MH. Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline #8: the fetus at risk for anemia – diagnosis and management. Am J Obstet Gynecol. 2015; 212: 697–710.CrossRef Google Scholar

Adama van Scheltema, PN, Borkent, S, Sikkel, E, Oepkes, D, Vandenbussche, FP. Fetal brain hemodynamic changes in intrauterine transfusion: influence of needle puncture site. Fetal Diagn Ther. 2009; 26: 131–3.Google Scholar

Moise, KJ Jr., Carpenter, RJ Jr., Kirshon, B, Deter, RL, Sala, JD, Cano, LE. Comparison of four types of intrauterine transfusion: effect on fetal hematocrit. Fetal Ther. 1989; 4: 126–37.Google Scholar

Zwiers, C, Lindenburg, ITM, Klumper, FJ, de Haas, M, Oepkes, D, Van Kamp, IL. Complications of intrauterine intravascular blood transfusion: lessons learned after 1678 procedures. Ultrasound Obstet Gynecol. 2017; 50: 180–6.Google Scholar

Detti, L, Oz, U, Guney, I, Ferguson, JE, Bahado-Singh, RO, Mari, G. Doppler ultrasound velocimetry for timing the second intrauterine transfusion in fetuses with anemia from red cell alloimmunization. Am J Obstet Gynecol. 2001; 185: 1048–51.Google Scholar

Weiner, CP, Williamson, RA, Wenstrom, KD, Sipes, SL, Widness, JA, Grant, SS, Estle, L. Management of fetal hemolytic disease by cordocentesis. II. Outcome of treatment. Am J Obstet Gynecol. 1991; 165: 1302–7.Google Scholar

Scheier, M, Hernandez-Andrade, E, Fonseca, EB, Nicolaides, KH. Prediction of severe fetal anemia in red blood cell alloimmunization after previous intrauterine transfusions. Am J Obstet Gynecol. 2006; 195: 1550–6.Google Scholar

Tiblad, E, Kublickas, M, Ajne, G, Bui, TH, Ek, S, Karlsson, A, Wikman, A, Westgren, M. Procedure-related complications and perinatal outcome after intrauterine transfusions in red cell alloimmunization in Stockholm. Fetal Diagn Ther. 2011; 30: 266–73.Google Scholar

Pasman, SA, Claes, L, Lewi, L, Van Schoubroeck, D, Debeer, A, Emonds, M, Geuten, E, De Catte, L, Devlieger, R. Intrauterine transfusion for fetal anemia due to red blood cell alloimmunization: 14 years experience in Leuven. Facts Views Vis Obgyn. 2015; 7: 129–36.Google Scholar

Sainio, S, Nupponen, I, Kuosmanen, M, Aitokallio-Tallberg, A, Ekholm, E, Halmesmäki, E, Orden, MR, Palo, P, Raudaskoski, T, Tekay, A, Tuimala, J, Uotila, J, Stefanovic, V. Diagnosis and treatment of severe hemolytic disease of the fetus and newborn: a 10-year nationwide retrospective study. Acta Obstet Gynecol Scand. 2015; 94: 383–90.Google Scholar

Lindenburg, IT, Wolterbeek, R, Oepkes, D, Klumper, FJ, Vandenbussche, FP, van Kamp, IL. Quality control for intravascular intrauterine transfusion using cumulative sum (CUSUM) analysis for the monitoring of individual performance. Fetal Diagn Ther. 2011; 29: 307–14.Google Scholar

Zwiers, C, Oepkes, D, Lopriore, E, Klumper, FJ, De Haas, M, van Kamp, IL. The near disappearance of fetal immune hydrops in relation to current state‐of‐the‐art management of red cell alloimmunization. Prenat Diagn. 2018; 38: 943–50.Google Scholar

van Kamp, IL, Klumper, FJ, Bakkum, RS, Oepkes, D, Meerman, RH, Scherjon, SA, Kanhai, HH. The severity of immune fetal hydrops is predictive of fetal outcome after intrauterine treatment. Am J Obstet Gynecol. 2001; 185: 668–73.Google Scholar

Ree, IMC, Smits-Wintjens, V, van der Bom, JG, van Klink, JMM, Oepkes, D, Lopriore, E. Neonatal management and outcome in alloimmune hemolytic disease. Expert Rev Hematol. 2017; 10: 607–16.Google Scholar

Lindenburg, IT, Smits-Wintjens, VE, van Klink, JM, Verduin, E, van Kamp, IL, Walther, FJ, et al. Long-term neurodevelopmental outcome after intrauterine transfusion for hemolytic disease of the fetus/newborn: the LOTUS study. Am J Obstet Gynecol. 2012; 206: 141. e1–8.Google Scholar

Zwiers, C, van der Bom, JG, van Kamp, IL, van Geloven, N, Lopriore, E, Smoleniec, J, et al. Postponing Early Intrauterine Transfusion with Intravenous immunoglobulin Treatment; the PETIT study on severe hemolytic disease of the fetus and newborn. Am J Obstet Gynecol. 2018; 219: e1–291. e9.Google Scholar

Bowman, JM. Antenatal suppression of Rh alloimmunization. Clin Obstet Gynecol. 1991; 34: 296–303.CrossRef Google Scholar PubMed

Giannina, G, Moise, KJ Jr., Dorman, K. A simple method to estimate volume for fetal intravascular transfusions. Fetal Diagn Ther. 1998; 13: 94–7.Google Scholar